Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing to provide detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. 31 centers responded positively and we included all patients between 1/2017-7/2019 treated with ECP or ruxolitinib for moderate or severe SR-cGVHD. We identified 84 and 57 patients with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-cGVHD (steroid dependent vs. refractory vs. intolerant to steroids). At day+180 after initiation of treatment for SR-cGVHD the odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.35 (95% CI = [0.64; 2.91], p = 0.43). In line, we detected no statistically significant differences in overall survival, progression-free survival, non-relapse mortality and relapse incidence. The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-cGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-cGVHD.

Penack, O., Peczynski, C., Boreland, W., Lemaitre, J., Reinhardt, H. C., Afanasyeva, K., Avenoso, D., Holderried, T. A. W., Kornblit, B. T., Gavriilaki, E., Martinez, C., Chiusolo, P., Mico, M. C., Dagunet, E., Wichert, S., Ozdogu, H., Piekarska, A., Kinsella, F., Basak, G. W., Schoemans, H., Koenecke, C., Moiseev, I., Peric, Z., ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party, <<BONE MARROW TRANSPLANTATION>>, 2024; 59 (3): 380-386. [doi:10.1038/s41409-023-02174-2] [https://hdl.handle.net/10807/274564]

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Chiusolo, Patrizia;
2024

Abstract

Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing to provide detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. 31 centers responded positively and we included all patients between 1/2017-7/2019 treated with ECP or ruxolitinib for moderate or severe SR-cGVHD. We identified 84 and 57 patients with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-cGVHD (steroid dependent vs. refractory vs. intolerant to steroids). At day+180 after initiation of treatment for SR-cGVHD the odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.35 (95% CI = [0.64; 2.91], p = 0.43). In line, we detected no statistically significant differences in overall survival, progression-free survival, non-relapse mortality and relapse incidence. The clinical significance is limited by the retrospective study design and the current data can’t replace prospective studies on ECP in SR-cGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-cGVHD.
2024
Inglese
Penack, O., Peczynski, C., Boreland, W., Lemaitre, J., Reinhardt, H. C., Afanasyeva, K., Avenoso, D., Holderried, T. A. W., Kornblit, B. T., Gavriilaki, E., Martinez, C., Chiusolo, P., Mico, M. C., Dagunet, E., Wichert, S., Ozdogu, H., Piekarska, A., Kinsella, F., Basak, G. W., Schoemans, H., Koenecke, C., Moiseev, I., Peric, Z., ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party, <<BONE MARROW TRANSPLANTATION>>, 2024; 59 (3): 380-386. [doi:10.1038/s41409-023-02174-2] [https://hdl.handle.net/10807/274564]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/274564
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact